Glecaprevir and pibrentasvir (Mavyret) is indicated for the treatment of chronic hepatitis C virus genotype 1-6 infections without cirrhosis or with compensated cirrhosis.
Glecaprevir and pibrentasvir (Mavyret) is a fixed-dose combination indicated for the treatment of adult and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotypes 1-6 infections without cirrhosis or with compensated cirrhosis.
The dose would be 300/120 mg to be taken with food for a duration of 8 weeks. With Epclusa, it would be 400/100 mg to be taken for a duration of 12 weeks.
The recommendation should also extend to medication reconciliation by a pharmacist, informing patients with comorbidities, such as diabetes, about hypoglycemia symptoms, informing patients taking warfarin for anticoagulation changes, continuous lab monitoring, and physician visit and support programs.
In patients receiving Mavyret, the most reported adverse effects (greater than 10%) are headache and fatigue.